Testing a new immunotherapy drug combined with chemotherapy for advanced nasopharyngeal cancer

Plain-English translation of NCT06457503 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This trial is testing a combination treatment for people whose nasopharyngeal cancer has come back or spread to other parts of the body after initial treatment. The combination includes , an immunotherapy drug designed to help your immune system fight cancer, plus two standard chemotherapy drugs ( or , and ). Researchers want to see how well this three-drug combination works compared to what we know about chemotherapy alone.

Nasopharyngeal cancer that returns or spreads is very difficult to treat, and current chemotherapy options have limited success. By combining the new immunotherapy with chemotherapy, doctors hope to improve how many patients respond to treatment and potentially help them live longer.

Do you qualify?

You likely qualify if…

you have been diagnosed with nasopharyngeal cancer that has come back or spread to other parts of your body
your cancer has been confirmed by a biopsy or tissue sample
you have not received any systemic chemotherapy treatments for your recurrent or metastatic cancer before
your cancer is measurable on imaging scans (CT or MRI)
you meet basic health requirements to tolerate chemotherapy and immunotherapy

You likely don't qualify if…

you have untreated or active cancer that has spread to your brain
you are currently taking or have recently taken steroids at high doses
your cancer is growing so rapidly that it's causing severe symptoms like uncontrolled bleeding or pain
your cancer could be treated with surgery or radiation aimed at curing it instead
you received chemotherapy for your recurrent cancer within the last 6 months

What participation looks like

You would receive the three-drug combination (the immunotherapy medication plus two chemotherapy drugs) during a treatment phase lasting several months, given through infusions on a regular schedule. After this initial phase, if the treatment is working, you would continue taking the immunotherapy medication alone as a maintenance treatment to help keep the cancer under control. You would have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(13 sites)

United States

University of Arkansas for Medical Sciences, Little Rock, Arkansas

University of California, Irvine, Irvine, California

University of California, San Francisco, San Francisco, California

Emory Winship Cancer Institute, Atlanta, Georgia

Boston Medical Center, Boston, Massachusetts